The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1539
ISSUE1539
January 29, 2018
Neratinib (Nerlynx) for HER2-Positive Breast Cancer
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Neratinib (Nerlynx) for HER2-Positive Breast Cancer
January 29, 2018 (Issue: 1539)
The FDA has approved the oral tyrosine kinase
inhibitor neratinib (Nerlynx – Puma Biotechnology)
for extended adjuvant treatment of adults with early-stage,
human epidermal growth factor receptor 2
(HER2)-positive breast cancer, following...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.